FASEB J. Thermo Fisher Scientific
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by RECCHIA, A.
Right arrow Articles by GIUSTI, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by RECCHIA, A.
Right arrow Articles by GIUSTI, P.
(The FASEB Journal. 2004;18:617-626.)
© 2004 FASEB

{alpha}-Synuclein and Parkinson’s disease

ALESSANDRA RECCHIA1, PATRIZIA DEBETTO1, ALESSANDRO NEGRO*, DIEGO GUIDOLIN{dagger}, STEPHEN D. SKAPER{ddagger} and PIETRO GIUSTI2

Department of Pharmacology and Anesthesiology,
* "Centro di Ricerche in Biotecnologie Innovative,"
{dagger} Department of Human Anatomy and Physiology, University of Padova, 35131 Padova, Italy; and
{ddagger} Neurology and GI Centre of Excellence for Drug Discovery, GlaxoSmithKline Research and Development Limited, Harlow, Essex CM19 5AW, U.K.

2Correspondence: Department of Pharmacology and Anesthesiology, L.go Meneghetti, 2, 35131 Padova, Italy. E-mail: pietro.giusti{at}unipd.it


   ABSTRACT
TOP
ABSTRACT
BACKGROUND
LOCALIZATION AND STRUCTURE OF...
PHYSIOLOGICAL FUNCTIONS OF...
PATHOPHYSIOLOGY OF {alpha}-SYN
ANIMAL MODELS OF PD
CONCLUSIONS
REFERENCES
 
Alpha-synuclein ({alpha}-syn) is a small soluble protein expressed primarily at presynaptic terminals in the central nervous system. Interest in {alpha}-syn has increased dramatically after the discovery of a relationship between its dysfunction and several neurodegenerative diseases, including Parkinson’s disease (PD). The physiological functions of {alpha}-syn remain to be fully defined, although recent data suggest a role in regulating membrane stability and neuronal plasticity. Various trigger factors, either environmental or genetic, can lead to a cascade of events involving misfolding or loss of normal function of {alpha}-syn. In dopaminergic neurons, this may promote a vicious cycle in which elevation in cytoplasmic dopamine, oxidative stress, {alpha}-syn dysfunction, and disruption of vesicle function lead to dopaminergic cell loss and PD. {alpha}-Syn dysfunction appears to be a common feature of all forms of PD. The mechanism by which {alpha}-syn induces neuronal cell toxicity may invoke multiple pathways, such as aggregation or interaction with other proteins and molecules, including synphilin-1, chaperone 14-3-3 protein, and dopamine itself. This complexity has hindered the development of models to study PD. The available animal models of PD, each present distinct advantages and limits. Findings to date suggest that {alpha}-syn-based models represent a paradigm, which is closest to the human pathology.—Recchia, A., Debetto, P., Negro, A., Guidolin, D., Skaper, S. D., Giusti, P. {alpha}-Synuclein and Parkinson’s disease.


Key Words: {alpha}-synuclein aggregation • dopaminergic neurons • animal models of Parkinson’s disease


   BACKGROUND
TOP
ABSTRACT
BACKGROUND
LOCALIZATION AND STRUCTURE OF...
PHYSIOLOGICAL FUNCTIONS OF...
PATHOPHYSIOLOGY OF {alpha}-SYN
ANIMAL MODELS OF PD
CONCLUSIONS
REFERENCES
 
PARKINSON'S DISEASE (PD) is the second most common progressive neurodegenerative brain disorder of humans, after Alzheimer’s disease. PD affects ~1% of people beyond 65 years of age (1) , with a higher prevalence in men (2) ; it usually manifests itself in the fifth or sixth decade of life. PD is characterized clinically by severe motor symptoms including uncontrollable resting tremor, muscular rigidity, impaired postural reflexes, and bradykinesia, which vary between patients (for review, see refs 3 , 4 ). These abnormalities can be accompanied by other symptoms, such as autonomic dysfunction, depression, and a general slowing of intellectual processes (5) . Pathologically, PD is characterized by the marked degeneration of dopaminergic neurons in the substantia nigra pars compacta, which leads to the depletion of dopamine (DA) in its striatal projections, and of other brainstem neurons, with consequent disruption of the cerebral neuronal systems responsible for motor functions (for review, see refs 3 , 4 ). This neurodegeneration is accompanied by the presence of cytoplasmic (Lewy bodies, LBs) and neuritic (Lewy neurites, LNs) inclusions (6) in the surviving dopaminergic neurons and other affected regions of the central nervous system (CNS), but the mechanism underlying their formation is unclear, as is their pathogenic relevance.

PD is an essentially sporadic neurodegenerative disease whose pathogenesis remains largely unknown, despite years of intense research in an attempt to explain the complexity and the relative selectivity of dopaminergic neurodegeneration. Genetic and environmental risk factors (7) have gained more attention of late as possible causes of PD, but their relative contributions in initiating the neurodegenerative process continue to be debated. Based on current knowledge, late-onset idiopathic PD is thought to result from a complex interaction among multiple predisposing genes and environmental factors. In addition to sporadic forms of PD, several rare monogenic familial forms of the disease, characterized by early-onset and an autosomal dominant or recessive pattern of inheritance have been identified. Mutations in four genes have been clearly linked to PD encoding {alpha}-synuclein ({alpha}-syn) (8) , parkin (9) , ubiquitin carboxy-terminal hydrolase L-1 (10) , and DJ-1 (11) . Other genes or loci that may cause PD have been mapped in families (for review, see refs 4 , 12 13 14 ).

Although familial forms of PD with specific genetic defects represent only a minor part (<10%) of all cases, they may help to identify key abnormalities in protein pathways that are likely to be involved in the more common, multifactorial sporadic form of the disease. Mutations in the gene encoding for {alpha}-syn have received a great deal of attention with the discovery that fibrillar {alpha}-syn aggregates are the major components of both LBs and LNs (15 , 16) , characterizing most familial and sporadic PD. This observation suggests that although {alpha}-syn is infrequently mutated in PD, other cellular processes that could lead to abnormal metabolism and accumulation of this protein might play an important role in the pathogenesis of sporadic as well as familial disease.

This review provides a general overview of newer research on {alpha}-syn neurobiology potentially relevant to the causes of PD. Results from transgenic and nontransgenic {alpha}-syn animal models of PD are also reviewed for their contribution to an understanding of normal and pathophysiological roles of {alpha}-syn in the brain.


   LOCALIZATION AND STRUCTURE OF {alpha}-SYN
TOP
ABSTRACT
BACKGROUND
LOCALIZATION AND STRUCTURE OF...
PHYSIOLOGICAL FUNCTIONS OF...
PATHOPHYSIOLOGY OF {alpha}-SYN
ANIMAL MODELS OF PD
CONCLUSIONS
REFERENCES
 
{alpha}-Syn belongs to the synuclein family that includes ß-syn and {gamma}-syn (17 , 18) , which so far have been described only in vertebrates. {alpha}-Syn and ß-syn are predominantly expressed in brain at presynaptic terminals, particularly in the neocortex, hippocampus, striatum, thalamus, and cerebellum (19 , 20) . {gamma}-Syn is highly expressed in various areas of the brain, particularly in the substantia nigra, and has been found to be overexpressed in some breast and ovarian tumors (21) . The {alpha}-syn, ß-syn, and {gamma}-syn genes have been mapped to human chromosomes 4q21 (22) , 5q35 (22) , and 10q23 (21) , respectively. The sequences of all synucleins are similar (18) , although only {alpha}-syn is implicated in disease. {alpha}-Syn was originally identified in the electric organ of the Pacific electric eel Torpedo Californica (23) . Hundreds of well-conserved {alpha}-syn protein homologues exist in human, bird, mouse, bovine, and rat, but no homologues have been reported in lower organisms such as Escherichia coli, yeast, C. elegans, or Drosophila. Human {alpha}-syn is an abundant presynaptic protein with a perinuclear localization first identified as the precursor of a peptide, called the non-Aß component (NAC), present in extracellular amyloid plaques in some forms of Alzheimer’s disease patients (17 , 19) . {alpha}-Syn is an extremely heat-resistant, small acidic protein (14 kDa) composed of 140 amino acid (aa) residues (17) . {alpha}-Syn is a soluble, natively unfolded protein with an extended structure primarily composed of random coils (24) , but it may acquire secondary structural elements upon interaction with a number of ligands and proteins (25) that likely alter its native state conformation and lead to {alpha}-syn adopting partially folded conformations.

The sequence of {alpha}-syn can be subdivided into three distinct domains (Fig. 1 ). The highly conserved amino-terminal domain of {alpha}-syn (residues 1-65) includes six copies of an unusual 11 aa imperfect repeat that display variations of a KTKEGV consensus sequence and is unordered in solution, but can shift to an {alpha}-helical conformation (18 , 26) that appears to consist of two distinct {alpha}-helixes interrupted by a short break (27) . The amphipathic {alpha}-helixes (28) are reminiscent of the lipid binding domains of class A2 apolipoproteins (29) . In agreement with these structural features, {alpha}-syn avidly binds to negatively charged phospholipids and becomes {alpha}-helical upon binding (24 , 25 , 29) , suggesting that the protein may normally be membrane associated (29) . Several recent studies (30 31 32) have shown that lipidic environments that promote {alpha}-syn folding also accelerate {alpha}-syn aggregation, suggesting that the lipid-associated conformation of {alpha}-syn may be relevant to {alpha}-syn misfolding in neurodegenerative diseases. The {alpha}-helix forming domain hosts two independent missense mutations (Fig. 1) at position 53, changing an Ala to Thr (A53T), and at position 30, changing an Ala to Pro (A30P); these have been shown to cause autosomal dominant heritable early-onset PD (33) . The A53T mutation has been identified in a large Italian-Greek family (Contursi kindred) (8) that had autosomal dominant PD with LBs. The second mutation, A30P, was later found in a small German family with PD (34) . These mutations may make it easier for {alpha}-syn to be in the random coil state so that aggregation is more likely to occur. It has been suggested that this may be due to acquisition of a ß-sheet configuration by the protein, which renders it more prone to aggregation and filament formation. It has been shown (35) that the A30P and A53T mutations increase the rate of {alpha}-syn oligomerization, whereas the rate of mature fibril formation is increased and decreased by A53T and A30P mutations, respectively.



View larger version (30K):
[in this window]
[in a new window]
 
Figure 1. Human {alpha}-syn sequence and domains. The imperfect KTKEGV repeats are shown by violet columns. Missense mutations at residues 30 (A30P) and 53 (A53T) are shown in red. For further details, refer to text.

The central hydrophobic domain of {alpha}-syn (residues 66-95) is known as the non-Aß component of plaque (NAC) (17) , the second major component of brain amyloid plaques in Alzheimer’s disease (17 , 36) . It comprises the highly amyloidogenic part of the molecule that is responsible for the ability of {alpha}-syn to undergo a conformational change from random coil to ß-sheet structure (37) and to form Aß-like protofibrils and fibrils (36 , 37) . These features distinguish {alpha}-syn from ß-syn and {gamma}-syn, which fail to form copolymers with {alpha}-syn (36) . NAC region carries a phosphorylation site on Ser 87 (38) .

The acidic carboxyl-terminal domain (residues 96-140) of {alpha}-syn has no recognized structural elements but has a strong negative charge composed primarily of acidic amino acids (18) . Different from the amphipathic amino-terminal and the hydrophobic NAC regions, which are highly conserved between species, the carboxyl-terminal region is highly variable in size and in sequence (21) . It hosts an acidic domain (residues 125-140) that appears critical for the chaperone-like activity of {alpha}-syn (39 ; see section "Chaperone-like activity of {alpha}-syn"), as demonstrated by deletion mutants of the carboxyl-terminal region in which the {alpha}-syn chaperone activity is lost (40 , 41) . Several phosphorylation sites (Fig. 1) have been detected in the carboxyl-terminal region on Tyr-125, -133, and -136, and on Ser-129 (42) . Tyr-125 residues can be phosphorylated by two Src family protein tyrosine kinases, c-Src and Fyn (43 , 44) . Phosphorylation by Src family kinases does not suppress or enhance the tendency of {alpha}-syn to polymerize. {alpha}-Syn has proved to be an outstanding substrate for protein tyrosine kinase p72syk (Syk) in vitro; once it is extensively Tyr-phosphorylated by Syk or tyrosine kinases with similar specificity, it loses the ability to form oligomers, suggesting a putative anti-neurodegenerative role for these tyrosine kinases (42) . Considering that the carboxyl-terminal domain of {alpha}-syn is required for its chaperone-like activity (39) , it is conceivable that phosphorylation of these Tyr residues in this region would also affect this property of {alpha}-syn. However, whether in vivo Tyr-phosphorylation of {alpha}-syn is mediated by Syk or by another protein tyrosine kinase with overlapping site specificity remains an open question. {alpha}-Syn can be Ser-phosphorylated by protein kinases CKI and CKII (38) . The residue Ser-129 is also phosphorylated by G-protein-coupled receptor protein kinases (45) . Studies in vitro suggest that phosphorylation at Ser-129 promotes formation of {alpha}-syn filaments as well as oligomers (46) as a consequence of a change in charge distribution and hydrophobicity of {alpha}-syn carboxyl-terminal region (47) . Extensive and selective phosphorylation of {alpha}-syn at Ser-129 is evident in synucleinopathy lesions, including LBs (46) . Other post-translational modifications in the carboxyl-terminal, including glycosylation on Ser-129 (47) and nitration on Tyr-125, -133, and -136 (48) , may affect aggregation of {alpha}-syn. A O-glycosylated form of {alpha}-syn ({alpha}Sp22), a specific substrate for ubiquitination by parkin, has been identified by Shimura et al. (9) . Although it has not been determined where {alpha}-syn is glycosylated, a potential target for glycosylation is the carboxyl-terminal Ser-129, hosting O-linked sugars (9) . Truncation of the carboxyl-terminal region by proteolysis has been reported to play a role in {alpha}-syn fibrillogenesis in various neurodegenerative diseases (35) . Full-length as well as partially truncated and insoluble aggregates of {alpha}-syn have been detected in highly purified LBs (49) .


   PHYSIOLOGICAL FUNCTIONS OF {alpha}-SYN
TOP
ABSTRACT
BACKGROUND
LOCALIZATION AND STRUCTURE OF...
PHYSIOLOGICAL FUNCTIONS OF...
PATHOPHYSIOLOGY OF {alpha}-SYN
ANIMAL MODELS OF PD
CONCLUSIONS
REFERENCES
 
Several lines of evidence suggest a role of {alpha}-syn in membrane-associated processes at the presynaptic level. In the Zebra finch, {alpha}-syn is transiently expressed in a telencephalic area associated with song acquisition during the critical period for song learning (50) . In bovine brain, {alpha}- and ß-syn are constitutive inhibitors of phospholipase D2 (51) , which catalyzes the hydrolysis of phosphatidylcholine to phosphatidic acid (PA), thus triggering secretory vesicle production (52) . {alpha}-Syn appears to bind vesicles with high levels of PA (29) , and it is possible that this protein may regulate membrane trafficking via vesicle budding or turnover (53) . {alpha}-Syn knockout mice exhibit enhanced DA release at nigrostriatal terminals only in response to paired electrical stimuli, suggesting that {alpha}-syn is an activity-dependent, negative regulator of dopaminergic neurotransmission (54) . {alpha}-Syn has been shown to bind to fast axonal transport vesicles. Depletion of {alpha}-syn from cultured primary hippocampal neurons by treatment with antisense oligonucleotides decreased the distal pool of presynaptic vesicles, as visualized by electron microscopy (55) .

Chaperone-like activity of {alpha}-syn
Chaperones are proteins that prevent irreversible protein aggregation and facilitate the correct folding of non-native proteins through regulated binding and release in vivo (56) . {alpha}-Syn has been suggested to function as a chaperone protein in vivo because, besides lipids (24 , 25 , 29) , it appears capable of interacting with a variety of ligands and cellular proteins (57 , 58) , thus modifying their activities. It has recently been reported that the amino-terminal portion of {alpha}-syn shares 40% aa homology with molecular chaperone 14-3-3 (57) , suggesting that the two proteins could subserve the same function. The molecular chaperone 14-3-3 is particularly abundant in brain, where it comprises ~1% of total soluble proteins (59) . Chaperone 14-3-3 accumulates in LBs, participates in neuronal development and cell growth control (60) , and prevents apoptosis by antagonizing BAD, a proapoptotic member of the Bcl-2 family (61 ; Fig. 2 ). {alpha}-Syn binds to many of the same proteins as 14-3-3 (57) , including three proteins known to affect cell viability, protein kinase C (PKC), BAD, and extracellular regulated kinase (ERK). {alpha}-Syn interacts with 14-3-3 (57) , and the interaction between the two proteins produces a 54 to 83 kDa protein complex in PD brain (58) . This complex is selectively increased in substantia nigra but not in cerebellum or cortex. Thus, {alpha}-syn may sequester 14-3-3, leading to a reduction in the amount of 14-3-3 protein available to inhibit apoptosis and rendering the cells more susceptible to cellular stresses (58 ; see also Fig. 2 ). Both 14-3-3 and {alpha}-syn bind to tyrosine hydroxylase (TH), the rate-limiting enzyme in catecholamine synthesis (see the section "Dopamine and {alpha}-syn"), with divergent consequences: activity is stimulated by 14-3-3 but inhibited by {alpha}-syn (51) .



View larger version (26K):
[in this window]
[in a new window]
 
Figure 2. {alpha}-Syn aggregation and toxic effects in dopaminergic neurons. A hypothetical scheme depicts various pathways that, leading to aggregation of natively unfolded {alpha}-syn, oxidative stress, or mitochondrial impairment, cause cell death. For further details, refer to text. DA, dopamine; DOPA, dihydroxyphenylalanine; LBs, Lewy bodies; MAO, monoamine oxidase; ROS, reactive oxygen species; TH, tyrosine hydroxylase; THP, phosphorylated tyrosine hydroxylase; Tyr, tyrosine; UPS, ubiquitin proteasome system.

The physical and functional homology between {alpha}-syn and 14-3-3 suggests that {alpha}-syn may normally act as a protein chaperone to help the cell deal with the effects of increased stress as part of an initial effort by the cell to protect itself against the accumulation of damaged proteins (57) . However, overexpression of wild-type {alpha}-syn is toxic to dividing cells and overexpression of its mutant forms A53T or A30P exhibits even greater toxicity (57) , which may be due to inhibition of PKC and interaction of {alpha}-syn with BAD, ERK, or other proteins involved in signal transduction (57) .


   PATHOPHYSIOLOGY OF {alpha}-SYN
TOP
ABSTRACT
BACKGROUND
LOCALIZATION AND STRUCTURE OF...
PHYSIOLOGICAL FUNCTIONS OF...
PATHOPHYSIOLOGY OF {alpha}-SYN
ANIMAL MODELS OF PD
CONCLUSIONS
REFERENCES
 
The first association between {alpha}-syn and neurodegenerative diseases was reported by Uéda et al. (17) . These authors showed that a short peptide, called NAC, present in purified amyloid plaques of Alzheimer’s disease patients, is derived from a larger precursor protein (then called non-amyloid component precursor or NACP), which we now know is {alpha}-syn. Two missense mutations, A53T (8) and A30P (34) , in the {alpha}-syn gene appear to account for rare cases of early-onset PD in families of European origin. The aggregation and accumulation of these abnormal {alpha}-syn proteins in dopaminergic neurons have been postulated to be responsible for the subsequent neurodegeneration (34) .

Very little is known about the structural basis for differences in the fibrillation between wild-type {alpha}-syn and its A53T and A30P mutants. Like the wild-type protein, A53T and A30P {alpha}-syn are natively unfolded under physiological conditions (62) , posing a crucial question as to how a single point mutation in the "disordered" conformation of the protein (i.e., natively unfolded) may affect its aggregation and fibrillation properties. {alpha}-Syn aggregation is present not only in autosomal dominant early-onset PD, but also in the classic form of PD and in other CNS disorders, called {alpha}-synucleinopathies, which include Alzheimer’s disease, Lewy body dementia, Hallervorden-Spatz syndrome, and multiple system atrophy (Table 1 ).


View this table:
[in this window]
[in a new window]
 
Table 1. Alpha-synucleinopathies

The assembly of {alpha}-syn is accompanied by transition from random coil to a ß-pleated sheet conformation (74) . X-ray fiber and electron diffraction studies show {alpha}-syn filaments to exhibit a cross-ß conformation, a characteristic feature of amyloid (75) . Common features of surviving dopaminergic neurons in PD are LBs and LNs (76) . The latter are found not only in substantia nigra, but also in dorsal motor nucleus of the vagus, nucleus basalis of Meynert, and locus coeruleus (77) . LBs are abnormal intracytoplasmic inclusions, 5–25 µm in diameter, structurally composed of a dense core and a clearer surrounding halo. Ultrastructurally, LBs contain an eosinophilic core of filamentous and granular material surrounded by radially oriented filaments. {alpha}-Syn is a major component both of LB filaments and of dystrophic LNs (62) .

There are no data implicating ß- and {gamma}-syn in neurological disorders. While these proteins are not found in LBs and LNs, it has been reported that patients affected by PD and dementia with LBs display hippocampal neurons containing {alpha}-, ß-, and {gamma}-syn (78) .

Aggregation mechanisms of {alpha}-syn
Abnormal protein aggregation appears to be a common feature in aging brain and in several neurodegenerative diseases, although a clear role in the disease process remains to be defined. In in vitro models, {alpha}-syn (or some of its truncated forms) readily assembles into filaments resembling those isolated from brain of patients with LB dementia and familiar PD (49) . The peptide derived from the central hydrophobic region of {alpha}-syn (NAC, see Fig. 1 ) represents a second major intrinsic constituent of Alzheimer’s plaques (28) .

Normal {alpha}-syn and its mutated forms (A53T and A30P) have a random coil conformation and do not form significant secondary structure in aqueous solution at low concentrations; however, at higher concentrations they are prone to self-aggregate, producing amyloid fibrils (79) . Several differences in the aggregation behavior of the PD-linked mutants and the wild-type protein have been documented. Monomeric {alpha}-syn aggregates in vitro to form stable fibrils via a metastable oligomeric (i.e., protofibril) state (80) . The protofibrillization rate of both mutants is higher than that of wild-type protein; the fibrillation rate is lower in A30P and higher in A53T (81 , 82) .

Several mechanisms for {alpha}-syn aggregation have been proposed (see Fig. 2 ); those involving the ubiquitin proteasome system (UPS) and oxidative stress have gained the most prominence until now. UPS is the primary biochemical pathway responsible for the degradation of normal and abnormal (mutated, misfolded, or unassembled) intracellular proteins (83) . Failure of this system leads to protein accumulation and cell death (84) . Degradation via UPS involves two successive steps: initially, the protein substrate is tagged by covalent attachment of multiple ubiquitin molecules through the action of ubiquitin-conjugating enzymes. Subsequently, the tagged protein is degraded by the 26S proteasome, with release of reusable ubiquitin (83) . The 26S proteasome belongs to the proteasome family of multicatalytic proteases and is located in the cytoplasm, endoplasmic reticulum, perinuclear region, and nucleus of eukaryotic cells (85) . A growing body of evidence suggests that ubiquitin-dependent protein degradation may be impaired in many neurodegenerative diseases, including PD and diffuse LB disease (DLBD).

A key pathological feature in PD and DLBD is the formation of ubiquitinated cytoplasmic inclusions (86) . In PD, LBs are formed within the dopaminergic neurons of the substantia nigra pars compacta. In DLBD, the LB-ubiquitin is in the form of polyubiquitin chains rather than ubiquitin monomers, as shown by biochemical analyses of isolated cortical LBs from postmortem tissue (87) . This observation suggests that polyubiquitinated proteins may accumulate in inclusions as a result of a dysfunction in the proteasome degradation process. Besides ubiquitin, LBs contain {alpha}-syn, subunits of the 26S proteasome, and other proteins including parkin, 14-3-3 protein (58) , and synphilin-1 (15) . The last forms a complex with {alpha}-syn, which is then ubiquitinated by the E3 ubiquitin ligase activity (88) . A mutation in parkin leads to autosomal recessive juvenile parkinsonism, which commonly lacks microscopic {alpha}-syn Lewy-type aggregates (89) . Despite the absence of LBs, selective accumulation of the putatively toxic {alpha}Sp22 has been demonstrated in parkin-linked PD brains (9) , suggesting that parkin mutations may predispose to accumulation of {alpha}-syn in a soluble nonfibrillar form. Taken together, these findings propose that UPS inactivity may contribute to the development of neurodegeneration in PD forms either or not characterized by LB formation.

Another mechanism underlying {alpha}-syn aggregation may involve the action of oxidants, which cause {alpha}-syn to aggregate and thereby perhaps initiate formation of toxic intermediate oligomers (90 , 91) , probably due to a kinetic stabilization of the {alpha}-syn protofibril by a dopamine-{alpha}-syn adduct (30) . Other in vitro studies have revealed that overexpression of {alpha}-syn can induce iron-dependent aggregation (see Fig. 2 ) (92) .

Dopamine and {alpha}-syn
One school of thought regarding PD pathogenesis is built around a role for reactive oxygen species (ROS), which can cause oxidative stress and mitochondrial impairment, and cell death (93) . The metabolism of DA in nigral neurons produces ROS and other highly reactive chemical species, such as DA-quinones and peroxynitrites, either by autoxidation or by MAO B-mediated oxidative deamination (94 95 96 ; see also Fig. 2 ). The production of ROS and quinones contributes to lipid peroxidation, DNA damage, inhibition of mitochondrial respiratory chain activity, and ultimately neuronal cell death (97) . Postmortem studies in PD patients provide strong evidence for increased oxidative stress in dopaminergic neurons of the substantia nigra, possibly caused by increased iron content (98) , impairment in mitochondrial function, depletion of reduced glutathione, overexpression of Cu, Zn-superoxide dismutase (99) , alterations in antioxidant protein levels, lipid peroxidation, protein nitration, and DNA damage (100 ; for a review, see ref 93 ; Fig. 2 ).

Overexpression of {alpha}-syn, especially its mutant forms, may enhance the vulnerability of neurons to DA-induced cell death through an excessive generation of intracellular ROS (101) . The degeneration of dopaminergic neurons may also occur because of a decrease in brain capacity to inactivate these reactive compounds (96) . Deficiencies in the antioxidant capacity in substantia nigra of PD patients have, in fact, been reported (102) .

Accumulation of {alpha}-syn, induced by transfection of wild-type human {alpha}-syn or the A53T or A30P PD-causing mutants triggered apoptosis (Fig. 2) of cultured human fetal dopaminergic neurons, while there is an increase in survival of cultured nondopaminergic human cortical neurons (58) . Mutants of {alpha}-syn induced neurotoxicity at lower {alpha}-syn concentrations than the wild-type protein in dopaminergic neurons and significantly reduced neuroprotective activity relative to wild-type protein in cortical neurons (58) . The dopaminergic specificity of {alpha}-syn neurotoxicity was directly related to endogenous DA production and consequent ROS generation, because inhibition of DA synthesis by the highly specific TH inhibitor {alpha}-methyl-p-tyrosine prevented {alpha}-syn-induced apoptosis in cultured dopaminergic neurons (58) . DA-dependent neurotoxicity was mediated by elevated levels of 54 to 83 kDa soluble protein complexes containing {alpha}-syn and 14-3-3 protein (Fig. 2) , which, by reducing the anti-apoptotic activity of 14-3-3, could increase neuronal vulnerability to ROS generated by endogenous DA metabolism (58) .

It has been reported that wild-type {alpha}-syn overexpression may regulate DA biosynthesis, acting on several enzymes that play different roles in this process. The activity of TH, the enzyme catalyzing the rate-limiting step in the biosynthesis of catecholamines (103) , may be negatively modulated by {alpha}-syn either interacting directly with the enzyme (104) or decreasing its gene expression (105) . In addition, aromatic acid DOPA decarboxylase gene expression is decreased by wild-type {alpha}-syn overexpression (105) . Since, for catalytic activity, TH requires tetrahydrobiopterin (BH4) as a cofactor, any event reducing BH4 availability decreases DA biosynthesis. Wild-type {alpha}-syn overexpression may also reduce DA synthesis by inhibiting the key enzymes involved in the production of BH4, including GTP cyclohydrolase and sepiapterin reductase (105) .

A reduction in free soluble {alpha}-syn may occur by down-regulation of {alpha}-syn mRNA or by stimuli that induce fibrillation. Disinhibition of {alpha}-syn activity may lead to an increase in DA concentration with subsequent generation of ROS. Collectively, these data point to a key role for {alpha}-syn in the regulation of DA synthesis. A loss in {alpha}-syn function consequent to its aggregation or decreased expression, as occurs in PD, may selectively disrupt DA homeostasis and negatively affect dopaminergic neuron survival (104) .


   ANIMAL MODELS OF PD
TOP
ABSTRACT
BACKGROUND
LOCALIZATION AND STRUCTURE OF...
PHYSIOLOGICAL FUNCTIONS OF...
PATHOPHYSIOLOGY OF {alpha}-SYN
ANIMAL MODELS OF PD
CONCLUSIONS
REFERENCES
 
The classical animal models of PD rely on the use of neurotoxins, including 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 6-hydroxydopamine (6-OHDA), and, more recently, the agricultural chemicals paraquat and rotenone, to deplete DA (Fig. 3 , left panel). These models are able to elicit motor deficits in different animal species, e.g., Drosophila, rats, mice, and primates, with the exception of MPTP, which fails to induce a significant dopaminergic neurodegeneration in rats (106 107 108) . However, neurotoxic models have some limitations regarding, in particular, the acute nature of the dopaminergic neuron loss, which does not allow for the identification of LBs with any of the neurotoxins used except rotenone (106) , thus reproducing only the terminal conditions of the human disease. A new neurotoxic PD model has been developed based on impairment of proteasomal function by intranigral injection of the selective proteasome inhibitor lactacystin (109 ; see also Fig. 3 , left panel). Inhibition of 20/26S proteasomal function in the substantia nigra pars compacta induced by lactacystin leads to protein accumulation and inclusion body formation, accompanied by a relatively selective degeneration of dopaminergic neurons and motor dysfunction. This model closely mirrors the neurodegenerative process that occurs in sporadic PD, but not its progressive development.



View larger version (40K):
[in this window]
[in a new window]
 
Figure 3. Animal models of Parkinson’s disease. The main PD clinical feature of each animal model are reported. For further details, refer to text. LBs, Lewy bodies; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine;6-OHDA, 6-hydroxydopamine; WT {alpha}-syn, wild-type {alpha}-synuclein.

In the attempt to better reproduce the key features of the human PD, particularly the progressive nature of neurodegeneration, a new approach in the development of PD models has been attempted based on the genetic and neuropathological links between {alpha}-syn and PD. This has produced some "transgenic" and "nontransgenic" {alpha}-syn animal models (106 107 108 ; see also Fig. 3 , middle and right panels).

Transgenic {alpha}-syn models
When human wild-type and mutant (A30P and A53T) {alpha}-syn are overexpressed in Drosophila, the flies develop an adult-onset, remarkably selective loss of DA neurons. This cell loss is associated with progressive motor dysfunction and with the presence of filamentous intraneuronal inclusions that contain {alpha}-syn (106) . It is not clear whether the observed motor deficits are due to DA neuron dysfunction, as there is no difference in the toxicity of wild-type and mutant {alpha}-syn (107) . In addition to Drosophila, several transgenic murine models overexpressing human {alpha}-syn have been developed (110) . Although none of these transgenic models faithfully reproduce PD, some do exhibit significant synucleinopathy-induced neurodegeneration, a key feature of human {alpha}-syn pathology. These limitations notwithstanding, {alpha}-syn transgenic mice represent useful tools to investigate the toxicity of {alpha}-syn in vivo and factors modulating the aggregation of {alpha}-syn in vivo (106) . It remains to be explained why these {alpha}-syn transgenic mice fail to display any significant DA neuron abnormalities, particularly in light of the dramatic pathological changes observed in Drosophila DA neurons and the DA-dependent {alpha}-syn toxicity seen in human neuronal cell cultures (58) . One possibility is that rodent DA neurons are especially resistant to {alpha}-syn toxicity, perhaps due to the relative levels of {alpha}-syn vs. ß-syn, {gamma}-syn, and other intrinsic protective factors. Further studies are needed to fully clarify this issue.

"Non transgenic" {alpha}-syn models
These models are based on delivering {alpha}-syn directly to the substantia nigra by means of viral vectors. The use of viral vectors to overexpress putative toxic proteins, such as {alpha}-syn, may offer distinct advantages over transgenic animal models. For example, viral vectors may be administered to virtually any location within the brain at any time during the life span of the animal, and are suitable for rats, which have greater utility than mice for behavioral studies (111) .

Injection of recombinant adeno-associated viral vectors expressing wild-type or the A53T mutated human {alpha}-syn into rat SN produced a selective damage (30 to 80%) in nigral dopaminergic neurons (112) . After 8 wk, striatal DA and TH levels were reduced by 40–50% and were accompanied by significant motor impairment in those animals where dopaminergic cell loss exceeded 50–60%. At 6 months, signs of neuronal cell body and axonal pathology had subsided, suggesting that surviving neurons had recovered from the initial insult even though {alpha}-syn expression remained high (112) . Similar results have been reported using a HIV-1-derived lentiviral vector associated with wild-type and mutant {alpha}-syn derived from either rats or humans (111) . A progressive loss in nigral and striatal dopaminergic neurons was observed upon intranigral injection, with accumulation of {alpha}-syn in cytoplasmic structures similar to LBs and LNs (111) .


   CONCLUSIONS
TOP
ABSTRACT
BACKGROUND
LOCALIZATION AND STRUCTURE OF...
PHYSIOLOGICAL FUNCTIONS OF...
PATHOPHYSIOLOGY OF {alpha}-SYN
ANIMAL MODELS OF PD
CONCLUSIONS
REFERENCES
 
There is now a large body of evidence to support the involvement of both environmental and genetic factors in PD development. It is not inconceivable that PD will be shown to be heterogeneous in its etiology, with underlying genetic factors in some cases and environmental factors predominating in other instances. {alpha}-Syn is highly expressed in the CNS and is likely to have an important role as a modulator of synaptic plasticity. Recent evidence implicates this protein under certain conditions as a toxin for the dopaminergic system through multiple and complex ways, which remain ill-defined at best. A more complete understanding of {alpha}-syn biology represents a fundamental tool in our comprehension of PD and may lead to the development of novel therapeutic strategies for treating this disease.


   ACKNOWLEDGMENTS
 
We are grateful to Stefano Lovison and David Rota for their excellent technical support. This work was supported by grants from MIUR (Ministero dell’Istruzione, dell’Università e della Ricerca) to P.D. and P.G.


   FOOTNOTES
 
1 These authors contributed equally to this work.

Received for publication August 18, 2003. Accepted for publication December 16, 2003.


   REFERENCES
TOP
ABSTRACT
BACKGROUND
LOCALIZATION AND STRUCTURE OF...
PHYSIOLOGICAL FUNCTIONS OF...
PATHOPHYSIOLOGY OF {alpha}-SYN
ANIMAL MODELS OF PD
CONCLUSIONS
REFERENCES
 

  1. Tanner, C. M. (1992) Occupational and environmental causes of parkinsonism. Occup. Med. 7,503-513
  2. Dluzen, D. E., McDermott, J. L. (2000) Gender differences in neurotoxicity of the nigrostriatal dopaminergic system: implications for Parkinson’s disease. J. Gend. Specif. Med. 3,36-42
  3. Lotharius, J., Brundin, P. (2002) Pathogenesis of Parkinson’s disease: dopamine, vesicles and alpha-synuclein. Nat. Rev. Neurosci. 3,932-942[CrossRef][Medline]
  4. Siderowf, A., Stern, M. (2003) Update on Parkinson disease. Ann. Intern. Med. 138,651-658[Abstract/Free Full Text]
  5. Berrios, G. E., Campbell, C., Politynska, B. E. (1995) Autonomic failure, depression and anxiety in Parkinson’s disease. Br. J. Psychiatry 166,789-792[Abstract/Free Full Text]
  6. Gomez-Tortosa, E., Newell, K., Irizarry, M. C., Albert, M., Growdon, J. H., Hyman, B. T. (1999) Clinical and quantitative pathologic correlates of dementia with Lewy bodies. Neurology 53,1284-1291[Abstract/Free Full Text]
  7. Warner, T. T., Schapira, A.H. (2003) Genetic and environmental factors in the cause of Parkinson’s disease. Ann. Neurol. 53(Suppl. 3),S16-S23discussion S23–S25
  8. Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 276,2045-2047[Abstract/Free Full Text]
  9. Shimura, H., Schlossmacher, M. G., Hattori, N., Frosch, M. P., Trockenbacher, A., Schneider, R., Mizuno, Y., Kosik, K. S., Selkoe, D. J. (2001) Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson’s disease. Science 293,263-269[Abstract/Free Full Text]
  10. Leroy, E., Boyer, R., Auburger, G., Leube, B., Ulm, G., Mezey, E., Harta, G., Brownstein, M. J., Jonnalagada, S., Chernova, T., et al (1998) The ubiquitin pathway in Parkinson’s disease. Nature (London) 395,451-452[CrossRef][Medline]
  11. Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O., Breedveld, G. J., Krieger, E., Dekker, M. C., Squitieri, F., Ibanez, P., Joosse, M., et al (2003) Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299,256-259[Abstract/Free Full Text]
  12. Polymeropoulos, M. H. (2000) Genetics of Parkinson’s disease. Ann. N.Y. Acad. Sci. 920,28-32[Abstract/Free Full Text]
  13. Nussbaum, R. L., Ellis, C. E. (2003) Alzheimer’s disease and Parkinson’s disease. N. Engl. J. Med. 348,1356-1364erratum in. N. Engl. J. Med. 348, 2588[Free Full Text]
  14. Dawson, T. M., Dawson, V. L. (2003) Rare genetic mutations shed light on the pathogenesis of Parkinson disease. J. Clin. Invest. 111,145-151[CrossRef][Medline]
  15. Spillantini, M. G., Schmidt, M. L., Lee, V. M., Trojanowski, J. Q., Jakes, R., Goedert, M. (1997) Alpha-synuclein in Lewy bodies. Nature (London) 388,839-840[CrossRef][Medline]
  16. Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M., Goedert, M. (1998) Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. USA 95,6469-6473[Abstract/Free Full Text]
  17. Uéda, K., Fukushima, H., Masliah, E., Xia, Y., Iwai, A., Yoshimoto, M., Otero, D. A., Kondo, J., Ihara, Y., Saitoh, T. (1993) Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. USA 90,11282-11286[Abstract/Free Full Text]
  18. George, J. M. (2002) The synucleins. Genome Biol. 3,3002-3006
  19. Iwai, A., Yoshimoto, M., Masliah, E., Saitoh, T. (1995) The precursor protein of non-A beta component of Alzheimer’s disease amyloid is a presynaptic protein of the central nervous system. Neuron 14,467-475[CrossRef][Medline]
  20. Nakajo, S., Shioda, S., Nakai, Y., Nakaya, K. (1994) Localization of phosphoneuroprotein 14 (PNP 14) and its mRNA expression in rat brain determined by immunocytochemistry and in situ hybridisation. Brain Res. Mol. Brain Res. 27,81-86[Medline]
  21. Lavedan, C. (1998) The synuclein family. Genome Res. 8,871-880[Abstract/Free Full Text]
  22. Spillantini, M. G., Divane, A., Goedert, M. (1995) Assignment of human alpha-synuclein (SNCA) and beta-synuclein (SNCB) genes to chromosomes 4q21 and 5q35. Genomics 27,379-381[CrossRef][Medline]
  23. Maroteaux, L., Campanelli, J. T., Scheller, R. H. (1988) Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 8,2804-2815[Abstract]
  24. Eliezer, D., Kutluay, E., Bussell, R., Jr, Browne, G. (2001) Conformational properties of alpha-synuclein in its free and lipid-associated states. J. Mol. Biol. 307,1061-1073[CrossRef][Medline]
  25. Li, J., Uversky, V. N., Fink, A. L. (2001) Effect of familial PD point mutations A30P and A53T on the structural properties, aggregation and fibrillation of human {alpha}-syn. Biochemistry 40,11604-11613[CrossRef][Medline]
  26. Kahle, P. J., Haass, C., Kretzschmar, H. A., Neumann, M. (2002) Structure/function of alpha-synuclein in health and disease: rational development of animal models for Parkinson’s and related diseases. J. Neurochem. 82,449-457[CrossRef][Medline]
  27. Chandra, S., Chen, X., Rizo, J., Jahn, R., Südho, T. C. (2003) A broken {alpha}-helix in folded {alpha}-synuclein. J. Biol. Chem. 278,15313-15318[Abstract/Free Full Text]
  28. Uversky, V. N., Fink, A. L. (2002) Amino acid determinants of alpha-synuclein aggregation: putting together pieces of the puzzle. FEBS Lett. 522,9-13[CrossRef][Medline]
  29. Davidson, W. S., Jonas, A., Clayton, D. F., George, J. M. (1998) Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 273,9443-9449[Abstract/Free Full Text]
  30. Conway, K. A., Rochet, J. C., Bieganski, R. M., Lansbury, P. T., Jr (2001) Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294,6-9
  31. Lee, H. J., Choi, C., Lee, S. J. (2002) Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. J. Biol. Chem. 277,671-678[Abstract/Free Full Text]
  32. Lee, H. J., Shin, S. Y., Choi, C., Lee, Y. H., Lee, S. J. (2002) Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors. J. Biol. Chem. 277,5411-5417[Abstract/Free Full Text]
  33. Clayton, D. F., George, J. M. (1999) Synucleins in synaptic plasticity and neurodegenerative disorders. J. Neurosci. Res. 58,120-129[CrossRef][Medline]
  34. Kruger, R., Kuhn, W., Muller, T., Woitalla, D., Graeber, M., Kosel, S., Przuntek, H., Epplen, J. T., Schols, L., Riess, O. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease. Nat. Genet. 18,106-108[CrossRef][Medline]
  35. Rochet, J. C., Conway, K. A., Lansbury, P. T. (2000) Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse {alpha}-synuclein. Biochemistry 39,10619-10626[CrossRef][Medline]
  36. Giasson, B. I., Murray, I. V. J., Trojanowski, J. Q., Lee, V. M. (2001) A hydrophobic stretch of 12 amino acid residues in the middle of {alpha}-synuclein is essential for filament assembly. J. Biol. Chem. 276,2380-2386[Abstract/Free Full Text]
  37. El-Agnaf, O. M., Irvine, G. B. (2002) Aggregation and neurotoxicity of alpha-synuclein and related peptides. Biochem. Soc. Trans. 30,559-565[CrossRef][Medline]
  38. Okochi, M., Walter, J., Koyama, A., Nakajo, S., Baba, M., Iwatsubo, T., Meijer, L., Kahle, P. J., Haass, C. (2000) Constitutive phosphorylation of the Parkinson’s disease associated alpha-synuclein. J. Biol. Chem. 275,390-397[Abstract/Free Full Text]
  39. Souza, J. M., Giasson, B. I., Chen, Q., Lee, V. M., Ischiropoulos, H. (2000) Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J. Biol. Chem. 275,18344-18349[Abstract/Free Full Text]
  40. Kim, T. D., Paik, S. R., Yang, C. H. (2002) Structural and functional implications of C-terminal regions of alpha-synuclein. Biochemistry 41,13782-13790[CrossRef][Medline]
  41. Park, S. M., Jung, H. Y., Kim, T. D., Park, J. H., Yang, C. H., Kim, J. (2002) Distinct roles of the N-terminal-binding domain and the C-terminal-solubilizing domain of {alpha}-synuclein, a molecular chaperone. J. Biol. Chem. 277,28512-28520[Abstract/Free Full Text]
  42. Negro, A., Brunati, A. M., Donella-Deana, A., Massimino, M. L., Pinna, L. A. (2002) Multiple phosphorylation of alpha-synuclein by protein tyrosine kinase Syk prevents eosin-induced aggregation. FASEB J. 16,210-212[Abstract/Free Full Text]
  43. Ellis, C. E., Schwartzberg, P. L., Grider, T. L., Fink, D. W., Nussbaum, R. L. (2001) Alpha-synuclein is phosphorylated by members of the Src family of protein-tyrosine kinases. J. Biol. Chem. 276,3879-3884[Abstract/Free Full Text]
  44. Nakamura, T., Yamashita, H., Takahashi, T., Nakamura, S. (2001) Activated Fyn phosphorylates alpha-synuclein at tyrosine residue 125. Biochem. Biophys. Res. Commun. 280,1085-1092[CrossRef][Medline]
  45. Pronin, A. N., Morris, A. J., Surguchov, A., Benovic, J. L. (2000) Synucleins are a novel class of substrates for G protein-coupled receptor kinases. J. Biol. Chem. 275,26515-26522[Abstract/Free Full Text]
  46. Fujiwara, H., Hasegawa, M., Dohmae, N., Kawashima, A., Masliah, E., Goldberg, M. S., Shen, J., Takio, K., Iwatsubo, T. (2002) Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 4,160-164[Medline]
  47. McLean, P. J., Hyman, B. T. (2002) An alternatively spliced form of rodent alpha-synuclein forms intracellular inclusions in vitro: role of the carboxy-terminus in alpha-synuclein aggregation. Neurosci. Lett. 323,219-223[CrossRef][Medline]
  48. Takahashi, T., Yamashita, H., Nakamura, T., Nagano, Y., Nakamura, S. (2002) Tyrosine 125 of alpha-synuclein plays a critical role for dimerization following nitrative stress. Brain Res. 938,73-80[CrossRef][Medline]
  49. Crowther, R. A., Jakes, R., Spillantini, M. G., Goedert, M. (1998) Synthetic filaments assembled from C-terminally truncated {alpha}-synuclein. FEBS Lett. 436,309-312[CrossRef][Medline]
  50. George, J. M., Jin, H., Woods, W. S., Clayton, D. F. (1995) Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 15,361-372[CrossRef][Medline]
  51. Jenco, J. M., Rawlingson, A., Daniels, B., Morris, A. J. (1998) Regulation of Phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins. Biochemistry 37,4901-4909[CrossRef][Medline]
  52. Chen, Y. G., Siddhanta, A., Austin, C. D., Hammond, S. M., Sung, T. C., Frohman, M. A., Morris, A. J., Shields, D. (1997) Phospholipase D stimulates release of nascent secretory vesicles from the trans-Golgi network. J. Cell Biol. 138,495-504[Abstract/Free Full Text]
  53. Rajagopalan, S., Andersen, J. K. (2001) Alpha-synuclein aggregation: is it the toxic gain of function responsible for neurodegeneration in Parkinson’s disease?. Mech. Ageing Dev. 122,1499-1510[CrossRef][Medline]
  54. Abeliovich, A., Schmitz, Y., Farinas, I., Choi-Lundberg, D., Ho, W. H., Castillo, P. E., Shinsky, N., Verdugo, J. M., Armanini, M., Ryan, A., et al (2000) Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25,239-252[CrossRef][Medline]
  55. Murphy, D. D., Rueter, S. M., Trojanowski, J. Q., Lee, V. M. (2000) Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J. Neurosci. 20,3214-3220[Abstract/Free Full Text]
  56. Slavotinek, A. M., Biesecker, L. G. (2003) Unfolding the role of chaperones and chaperonins in human disease. Trends Genet. 17,528-535
  57. Ostrerova, N., Petrucelli, L., Farrer, M., Mehta, N., Choi, P., Hardy, J., Wolozin, B. (1999) Alpha-synuclein shares physical and functional homology with 14-3-3 proteins. J. Neurosci. 19,5782-5791[Abstract/Free Full Text]
  58. Xu, J., Kao, S. Y., Lee, F. J., Song, W., Jin, L. W., Yankner, B. A. (2002) Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat. Med. 8,600-606[CrossRef][Medline]
  59. Boston, P. F., Jackson, P., Thompson, R. J. (1982) Human 14-3-3 protein, radioimmunoassay, tissue distribution, and cerebrospinal fluid levels in patients with neurological disorders. J. Neurochem. 38,1475-1482[Medline]
  60. Fu, H., Subramanian, R. R., Masters, S. C. (2000) 14-3-3 proteins: structure, function and regulation. Annu. Rev. Pharmacol. Toxicol. 40,617-647[CrossRef][Medline]
  61. Yuan, J., Yanker, B. A. (2000) Apoptosis in the nervous system. Nature (London) 407,802-809[CrossRef][Medline]
  62. Conway, K. A., Harper, J. D., Lansbury, P. T. (1998) Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med. 11,1318-1320
  63. McKeith, I. G., Burn, D. J., Ballard, C. G., Collerton, D., Jaros, E., Morris, C. M., McLaren, A., Perry, E. K., Perry, R., Piggott, M. A., et al (2003) Dementia with Lewy bodies. Semin. Clin. Neuropsychiatry 8,46-57[CrossRef][Medline]
  64. Suh, Y. H., Checler, F. (2002) Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer’s disease. Pharmacol. Rev. 54,469-525[Abstract/Free Full Text]
  65. Simard, M., van Reekum, R. (2001) Dementia with Lewy bodies in Down’s syndrome. Int. J. Geriatr. Psychiatry 16,311-320